肝动—门脉双重介入治疗肝癌的临床研究  

CLINICAL STUDY ON THE TREATMENT OF PRIMARY HEPATIC CARCINOMA WITH DOUBLE INTERFERENCE THROUGH HAPATIC ARTERY AND PORTAL VEIN

作　　者：李新丰[1] 吕国荣[1] 陈骥[1] 陈凌岩[1] 陈景林[1] 李华东[1] 邱建龙[1] 吴春林[1] 

机构地区：[1]福建医学院附属第二医院

出　　处：《肿瘤研究与临床》1996年第4期233-235,共3页Cancer Research and Clinic

摘　　要：报告了Ｘ线下经肝动脉化疗栓塞（ＴＡＣＥ）及超声下肝内门静脉化疗（ＰＨＰＣ）加癌内无水酒精注射（ＰＥＩＴ）的双重介入法治疗原发性肝癌（ＰＨＣ）２０例。随访１０～３８个月，死亡４例，９例生存超过２年，其中６例发现脾明显增大，３例食管下段静脉曲张。认为双重介入治疗是一种有效的可靠方法，多次ＴＡＣＥ及ＰＨＰＣ＋ＰＥＩＴ，易加重肝功能损害，治疗期间的保肝及支持疗法极为重要。During the past 40 months,20 patients with Primary hepatic carcinoma(PHC)were treated by transhepatic artery chemocmbolization therapy(TACE)with percutaneous intra-hepaticportal chemotherapy(PHPC)plus percutancous ethanol imtratumor(PEIT).After 10 to38 months follow-up, 4 advanced cases died,9 cases survived over 2 years and 6 of them werewith evident splenomegaly and 3 with varicosis in lower csophogus,In aceording to the clinicalexperience and outcome,we think that double interference methed is safe and effective but maydamage the hepatic function. It was important to protect the liver function and use supporting treatment.

关 键 词：肝癌 介入疗法 药物疗法 

分 类 号：R735.705[医药卫生—肿瘤]